Decisions 26th February 2013


Recent JFG Decisions

 

At the meeting on the 26th February 2013 following actions / changes to the formulary were agreed

 

New Drug Requests

 

Approved

Methylnaltrexone

  • Approved for use on the advice of palliative care team - TLS Blue

MagTab®

  • Approved for use by Renal Consultant only - TLS Red

Urocit K®

  • Approved for use by Renal Consultant only in patients for the treatment of distal renal tubular acidosis and hypocritaturia second line to Potassium Citrate BP Liquid - TLS Red

Doublebase Dayleve® Gel

  • Recommended to be added to formulary TLS Green

Ranolazine (NBT)

  • Recommended to be added to formulary in line with UHB TLS Red

 

Recommended but awaiting funding agreement - to be added once received

Alteplase and Dornase Alfa

  • Recommended to be added to the formulary NBT Pleural Services only TLS Red - awaiting funding agreement

 

Not Approved

Dapagliflozin

  • Not approved - await NICE TA publication

Botox for the treatment of Raynuard’s disease of the hand

  • Not approved

Suboxone

  • Not approved

Aflibercept (sequential use after Lucentis failure)

  • Not approved 

 

Specialised Commissioning

Ivacaftor

  • Specialised Commissioning policy - to be added to formuarly TLS Red

Hizentra Subcutaneous IVIg NBT

  • Recommended to be added as already on formulary for UHB TLS Red

Fingolimod for relasping remitting MS (not meeting NICE 254 criteria)

  • Not approved as this service is commissioned by Specialised Commissioning from 1st April 2013

 

Cancer Drugs Fund

Ruxolitinib

  • Individual patient request to be forwarded to the cancer drugs fund - not to be added to formuarly. Willl be considered for inclusion to formulary once NICE TA published

 

Last updated by: on 16-07-2013 08:30